We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




SIDS Blood Test Could Identify At-Risk Babies

By LabMedica International staff writers
Posted on 27 Jan 2025

Sudden infant death syndrome (SIDS) remains the leading cause of death in babies between one month and one year old, with its causes largely unexplained. More...

Researchers have now discovered blood markers linked to SIDS, paving the way for potential tests to identify infants at risk and contributing to understanding the underlying causes of the condition.

Researchers from the University of Virginia School of Medicine (Charlottesville, VA, USA) analyzed blood serum samples from infants who died of SIDS, identifying specific biological indicators that could help identify warning signs in babies and potentially save lives. In their study, the team examined 828 different metabolites involved in processes like nerve cell communication, stress response, and hormone regulation. These processes could contribute to SIDS.

The researchers found variations in certain fats, specifically sphingomyelins, which are vital for brain and lung development. These differences could disrupt these processes, potentially increasing the risk of SIDS in some infants. After adjusting for factors like age, sex, race, and ethnicity, they identified 35 biomarkers of SIDS, including ornithine—a substance critical for ammonia disposal in urine—and a lipid metabolite linked to brain and lung health. This lipid metabolite is also considered a potential indicator for fetal heart defects.

“The results of this study are very exciting – we are getting closer to explaining the pathways leading to a SIDS death,” said Dr. Fern R. Hauck, a family medicine physician at UVA Health, director of the Chicago Infant Mortality Study and a leading expert on SIDS. “Our hope is that this research lays the groundwork to help identify – through simple blood tests – infants who are at higher risk for SIDS and to save these precious lives.”

Related Links:
UVA School of Medicine


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.